Clinical Differences Between Continuous Flow Ventricular Assist Devices: A Comparison Between HeartMate II and HeartWare HVAD

• DOI: 10.1111/jocs.12158
• Publication Date: 2013-07-12T02:25:14Z
• Authors: Spencer D. Lalonde; Ana C. Alba; Alanna Rigobon; Heather J. Ross; Diego H. Delgado; Filio Billia; Michael McDonald; Robert J. Cusimano; Terrence M. Yau; Vivek Rao
• Keywords: Demographics; Destination therapy; Stroke

The HeartWare ventricular assist device (HVAD) is a new generation centrifugal flow VAD recently introduced in Canada. objective of this study was to compare the HVAD HeartMate II (HMII) axial device. Very few studies have compared clinical outcomes between newer VADs.All perioperative and follow-up data on LVAD recipients were collected prospectively our institutional database. Between January 2006 April 2012, 46 consecutive patients underwent implantation either an (n=13) or HMII (n=33) Pre-implant demographics, postoperative reviewed groups.Overall, baseline characteristics, co-morbidities laboratory values comparable two groups. majority Interagency Registry for Mechanical Assisted Circulatory Support 3-4 (92% both groups) most bridge transplant (75% vs. 79% HVAD). Survival incidence bleeding, renal dysfunction, liver infection similar However, devices had significantly higher gastrointestinal (GI) bleeding (31% 0% patients, p<0.01) stroke (44% 10% at one year p=0.04). Hemorrhagic strokes more frequent with (three five episodes three p=0.06).While complications comparable, experienced GI therefore refinement patients' management may decrease these complications.